BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jarvi NL, Balu-Iyer SV. Immunogenicity Challenges Associated with Subcutaneous Delivery of Therapeutic Proteins. BioDrugs 2021;35:125-46. [PMID: 33523413 DOI: 10.1007/s40259-020-00465-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Bergqvist V, Holmgren J, Klintman D, Marsal J. Letter: to switch or not to switch, that is the question-author's reply. Aliment Pharmacol Ther 2022;56:922-3. [PMID: 35934847 DOI: 10.1111/apt.17147] [Reference Citation Analysis]
2 Whitaker N, Pace S, Merritt K, Tadros M, Khossravi M, Deshmukh S, Cheng Y, Joshi SB, Volkin DB, Dhar P. Developability assessments of monoclonal antibody candidates to minimize aggregation during large-scale ultrafiltration and diafiltration (UF-DF) processing. Journal of Pharmaceutical Sciences 2022. [DOI: 10.1016/j.xphs.2022.08.001] [Reference Citation Analysis]
3 Dubbelboer IR, Sjögren E. Physiological based pharmacokinetic and biopharmaceutics modelling of subcutaneously administered compounds – an overview of in silico models. International Journal of Pharmaceutics 2022. [DOI: 10.1016/j.ijpharm.2022.121808] [Reference Citation Analysis]
4 Dubbelboer IR, Sjögren E. Overview of authorized drug products for subcutaneous administration: pharmaceutical, therapeutic, and physicochemical properties. European Journal of Pharmaceutical Sciences 2022. [DOI: 10.1016/j.ejps.2022.106181] [Reference Citation Analysis]
5 Jiskoot W, Hawe A, Menzen T, Volkin DB, Crommelin DJA. Ongoing Challenges to Develop High Concentration Monoclonal Antibody-based Formulations for Subcutaneous Administration: Quo Vadis? J Pharm Sci 2021:S0022-3549(21)00614-6. [PMID: 34813800 DOI: 10.1016/j.xphs.2021.11.008] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Bentley ER, Little SR. Local delivery strategies to restore immune homeostasis in the context of inflammation. Adv Drug Deliv Rev 2021;178:113971. [PMID: 34530013 DOI: 10.1016/j.addr.2021.113971] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
7 Li D, Chow PY, Lin TP, Cheow C, Li Z, Wacker MG. Simulate SubQ: The Methods and the Media. J Pharm Sci 2021:S0022-3549(21)00593-1. [PMID: 34728176 DOI: 10.1016/j.xphs.2021.10.031] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
8 Baker D, Asardag AN, Quinn OA, Efimov A, Kang AS. Anti-drug antibodies to antibody-based therapeutics in multiple sclerosis. Hum Antibodies 2021. [PMID: 34397407 DOI: 10.3233/HAB-210453] [Reference Citation Analysis]